Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, shares some insights into the biology of high-risk multiple myeloma, highlighting the role of TP53 mutation and various translocations in high-risk disease. Prof. Morgan also explains that there are major advances being made in our understanding of high-risk myeloma and several ongoing clinical trials addressing the outcomes of these patients. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.